Loading institutional data...
Loading institutional data...
Held by 503 of 5,944 reporting institutions (97th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Ranked against 1111 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | $1.05T | 51.0× | — | 16.1× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $679.0B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $620.1B | 23.4× | — | 6.6× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $435.4B | 104.3× | 31.4× | 7.1× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| UNH | $374.0B | 31.2× | 21.4× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| BDRX | $359.1B | — | — | — | — | — | — | — | — | — | 7 |
| MRK | $321.1B | 17.6× | — | 4.9× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| NVSEF | $289.9B | — | — | — | — | — | — | — | — | — | 2 |
| AZN | $250.4B | — | — | — | — | — | — | — | — | — | 1,248 |
| AMGN | $219.7B | 28.7× | 18.3× | 6.0× | 10.0% | 67.2% | 21.0% | 89.1% | 13.1% | 3.5× | 3,014 |
| TMO | $217.8B | 32.6× | 28.5× | 4.9× | 3.9% | — | 15.1% | 12.6% | 7.0% | 4.9× | 2,481 |
| ABT | $183.9B | 28.4× | 19.5× | 4.2× | 5.7% | 56.4% | 14.7% | 12.5% | 10.5% | 1.0× | 2,964 |
| GILD | $163.5B | 19.4× | 18.1× | 5.5× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| PFE | $146.7B | 19.0× | — | 2.3× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $141.1B | 39.5× | 29.3× | 5.7× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $133.2B | 47.7× | 36.6× | 13.2× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| SYK | $128.8B | 40.1× | 21.8× | 5.1× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| CVS | $126.0B | 71.3× | 12.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| VRTX | $123.1B | 31.6× | 26.9× | 10.3× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| MDT | $110.1B | 23.1× | 11.7× | 3.0× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| GLAXF | $106.9B | — | — | — | — | — | — | — | — | — | 5 |
| MCK | $102.7B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| SNYNF | $101.3B | — | — | — | — | — | — | — | — | — | 5 |
| HCA | $92.0B | 14.5× | — | 1.2× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $86.4B | 15.5× | 14.8× | 0.4× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| MOH | $10.0B | 21.9× | 9.7× | 0.2× | 11.7% | 13.1% | 1.0% | 11.6% | 6.0% | 3.9× | 503 |
Peers = companies sharing MOH's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
How management deployed cash over 10 years — and what it earned on reinvestment.
A balanced mix of reinvestment and shareholder returns.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 6%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $4.2B covers all $3.0B of scheduled principal — no refinancing pressure. Scheduled principal only (excludes interest & revolver draws). As of 2024-12-31 (10-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Coverage is adequate but not comfortable. Effective rate ~5.1% on $3.8B of debt.
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $195.14 today, the market must believe free cash flow compounds -3.5%/yr for a decade (off $1.1B normalized FCF).
2-stage DCF · 0.05B shares · net debt -$482M
mean 9.3% · volatility σ 187% · implied rate exceeded in 4/8 yrs
Central path = implied -3.5%/yr growth; shaded band = ±1σ (187%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Cash conversion lags reported earnings — watch accruals. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage rising year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $1.0B buybacks = $1.0B returned on -$636M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
EOD close · as of 2026-08-05 · 15d old
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $45.43B 100.0% | $40.65B 100.0% | $34.07B 100.0% | $31.97B 100.0% | $27.77B 100.0% | $19.42B 100.0% | $16.83B 100.0% | $18.89B 100.0% | $19.88B 100.0% | $17.78B 100.0% |
| Cost of Revenue | $39.49B 86.9% | $34.43B 84.7% | $28.67B 84.1% | $27.18B 85.0% | $23.70B 85.4% | $15.82B 81.4% | $13.90B 82.6% | — | — | — |
| Gross Profit | — | — | — | — | — | $2.48B 12.8% | $2.30B 13.7% | $2.52B 13.3% | $1.81B 9.1% | $1.73B 9.7% |
| Selling, General & Admin | $3.01B 6.6% | $2.74B 6.7% | $2.46B 7.2% | $2.31B 7.2% | $2.07B 7.4% | $1.48B 7.6% | $1.30B 7.7% | $1.33B 7.1% | $1.59B 8.0% | $1.39B 7.8% |
| Total Operating Expenses | $44.65B 98.3% | $38.94B 95.8% | $32.50B 95.4% | $30.80B 96.3% | $26.75B 96.3% | $18.34B 94.4% | $15.79B 93.8% | $17.76B 94.0% | $20.44B 102.8% | $17.48B 98.3% |
| Operating Income | $781.0M 1.7% | $1.71B 4.2% | $1.57B 4.6% | $1.17B 3.7% | $1.02B 3.7% | $1.08B 5.6% | $1.04B 6.2% | $1.13B 6.0% | -$555.0M -2.8% | $306.0M 1.7% |
| Interest Expense | $192.0M 0.4% | $118.0M 0.3% | $109.0M 0.3% | $110.0M 0.3% | $120.0M 0.4% | $102.0M 0.5% | $87.0M 0.5% | $115.0M 0.6% | $118.0M 0.6% | $101.0M 0.6% |
| Other Income (Expense), net | — | — | -$109.0M -0.3% | -$110.0M -0.3% | -$145.0M -0.5% | -$117.0M -0.6% | -$72.0M -0.4% | -$132.0M -0.7% | -$57.0M -0.3% | -$101.0M -0.6% |
| Pretax Income | $589.0M 1.3% | $1.59B 3.9% | $1.46B 4.3% | $1.06B 3.3% | $875.0M 3.2% | $961.0M 4.9% | $972.0M 5.8% | $999.0M 5.3% | -$612.0M -3.1% | $205.0M 1.2% |
| Income Tax Expense | $117.0M 0.3% | $410.0M 1.0% | $373.0M 1.1% | $271.0M 0.8% | $216.0M 0.8% | $288.0M 1.5% | $235.0M 1.4% | $292.0M 1.5% | -$100.0M -0.5% | $153.0M 0.9% |
| Net Income | $472.0M 1.0% | $1.18B 2.9% | $1.09B 3.2% | $792.0M 2.5% | $659.0M 2.4% | $673.0M 3.5% | $737.0M 4.4% | $707.0M 3.7% | -$512.0M -2.6% | $52.0M 0.3% |
| Per Share | ||||||||||
| EPS (Basic) | $8.93 | $20.52 | $18.91 | $13.72 | $11.40 | $11.40 | $11.85 | $11.57 | $-9.07 | $0.93 |
| EPS (Diluted) | $8.92 | $20.42 | $18.77 | $13.55 | $11.25 | $11.23 | $11.47 | $10.61 | $-9.07 | $0.92 |
| Weighted Avg Shares (Basic) | 52.8M | 57.4M | 57.7M | 57.8M | 57.8M | 59.0M | 62.2M | 61.1M | 56.4M | 55.4M |
| Weighted Avg Shares (Diluted) | 52.9M | 57.7M | 58.1M | 58.5M | 58.6M | 59.9M | 64.2M | 66.6M | 56.4M | 56.2M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
EOD close · as of 2026-08-05
No standout strengths flagged.
Where each multiple sits in its own 14-yr range · 45th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | — | 82.6 | 81.4 | 85.4 | 85.0 | 84.1 | 84.7 | 86.9 |
| Gross Profit | 13.3 | 13.7 | 12.8 | — | — | — | — | — |
| SG&A | 7.1 | 7.7 | 7.6 | 7.4 | 7.2 | 7.2 | 6.7 | 6.6 |
| Operating Income | 6.0 | 6.2 | 5.6 | 3.7 | 3.7 | 4.6 | 4.2 | 1.7 |
| Income Tax | 1.5 | 1.4 | 1.5 | 0.8 | 0.8 | 1.1 | 1.0 | 0.3 |
| Net Income | 3.7 | 4.4 | 3.5 | 2.4 | 2.5 | 3.2 | 2.9 | 1.0 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on MOH: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.